Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global leader in the field of analytical instruments and software solutions. For nearly six decades, the company has pioneered advancements in chromatography, mass spectrometry, and thermal analysis, catering to life, materials, and food sciences. Headquartered in Milford, Massachusetts, Waters Corp. operates directly in 35 countries, supported by approximately 8,000 employees and 15 manufacturing facilities globally.
Waters' main business segments include Waters, TA Instruments, VICAM, ERA, and Nonlinear Dynamics. The company's diverse product portfolio features ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns, mass spectrometry systems, and laboratory informatics solutions. These innovations empower laboratory-dependent organizations to achieve advancements in healthcare, environmental management, food safety, and water quality.
Waters Corporation serves a wide array of customers, including biopharmaceutical companies (57% of sales), industrial clients (31% of sales), and academic/government institutions (12% of sales). The company’s products are available in over 100 countries, ensuring a broad market reach.
Recent achievements include the launch of new accessories for TA Instruments Discovery Hybrid Rheometers, designed for battery formulation analysis, and the introduction of Oasis WAX/GCB and GCB/WAX Cartridges for PFAS analysis. These innovations reflect the company’s commitment to addressing emerging scientific challenges and regulatory requirements. Additionally, Waters continues to enhance its mass spectrometry capabilities with products like the ACQUITY QDa II Mass Detector and the Xevo MRT MS, aimed at accelerating research in pharmaceuticals, food, chemicals, and materials.
Financially, Waters Corporation reported first-quarter 2024 sales of $637 million, with a strategic focus on innovation and operational efficiency. Despite a 7% decrease in sales compared to the previous year, the company remains optimistic about future growth, driven by new product launches and higher growth areas.
Waters Corporation stands as a pivotal player in the analytical instruments industry, consistently driving scientific advancements and operational excellence.
Waters (NYSE: WAT) has introduced new bioseparations tools to accelerate and improve the development of RNA-based pharmaceuticals. The comprehensive set includes:
1. Novel digestion enzymes (RapiZyme MC1 and RapiZyme Cusativin) for complete RNA sequence coverage.
2. LC-MS-grade reagents (IonHance HFIP) to increase sensitivity and improve detection accuracy.
3. waters_connect MAP Sequence software for semi-automated workflows, reducing data processing time.
These tools simplify large molecule RNA analysis, supporting the development of mRNA vaccines, personalized cancer therapies, and drugs for genetic disorders. The new products aim to enhance sequence confirmation, modification analysis, and overall characterization of complex RNA molecules, potentially accelerating therapeutic development and lowering barriers for LC-MS non-experts.
Waters (NYSE:WAT) has introduced the TA Instruments™ Discovery Core Rheometer, a streamlined analyzer designed for routine manufacturing quality control and assurance laboratories. This compact system offers:
- Easy-to-use touchscreen interface with self-guided training, methods, and applications
- Superior performance at an affordable price, with up to 2x better torque sensitivity compared to similar rheometers
- Compact design requiring half the bench space of comparable modular rheometers
- Ability to handle multiple material types such as battery slurries, printing inks, food, and personal care products
The Discovery Core Rheometer is equipped with RheoGuide™ Software, providing immediate walk-up use and faster, real-time data analysis. It is orderable today, with worldwide availability in Q1 2025.
Waters (NYSE:WAT) has announced its Q3 2024 financial results conference call, scheduled for Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. The call will be broadcast live via webcast on the company's Investor Relations website. A replay will be available until November 29th, 2024.
Waters is a global leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis innovations. With a 65-year history, the company serves the life, materials, food, and environmental sciences sectors. Waters employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and its products are available in over 100 countries.
Waters (NYSE:WAT) has appointed Heather Knight to its Board of Directors, effective August 14, 2024. Knight, currently serving as Executive Vice President and Group President, Medical Products and Therapies at Baxter International, brings nearly three decades of experience in the pharmaceutical and medical device industries. Her appointment is expected to enhance the board's oversight of strategy and shareholder value.
Dr. Flemming Ornskov, Chair of the Board, praised Knight's proven track record in driving growth and innovation. Dr. Udit Batra, President and CEO of Waters , highlighted Knight's commitment to operational excellence and her global experience in commercial execution and portfolio innovation as complementary to the board's existing skills.
Waters (NYSE: WAT) reported Q2 2024 financial results with sales of $709 million, exceeding guidance but declining 4% as reported and in organic constant currency. GAAP EPS was $2.40, while non-GAAP EPS was $2.63, surpassing expectations due to strong operational performance. The company experienced better-than-expected performance in China and higher M&A contribution from Wyatt.
Key highlights include:
- Ex-China organic constant currency sales growth across Pharma, Industrial, and Academic & Government end markets
- Full-year outlook adjusted for a more gradual market improvement in H2 2024
- Pharmaceutical market sales decreased 3% as reported, 4% in organic constant currency
- Industrial market sales decreased 4% both as reported and in organic constant currency
- Academic and government market sales declined 15% as reported, 16% in organic constant currency
Waters (NYSE: WAT) has launched the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (RS-DSC), a high-throughput device for thermal stability testing of high-concentration biologic formulations. This innovative technology offers up to 24x faster testing and reduces sample volume requirements by 25x compared to competitor capillary DSC technologies.
The RS-DSC utilizes disposable microfluidic chips (MFCs) that enable up to 24 simultaneous measurements, streamlining the testing process for antibody drugs and engineered proteins. It provides more accurate data on high-concentration samples, avoiding the sensitivity challenges of differential scanning fluorescence (DSF) methods. The device also features automated software for rapid and in-depth analysis of thermodynamic properties.
Waters (NYSE: WAT) has announced its Q2 2024 earnings conference call will take place on July 31, 2024, at 8:00 a.m. Eastern Time. The event will be webcast live on the Waters Investor Relations website, with a replay available until August 28, 2024. Waters , a leader in analytical instruments and software, continues to serve diverse industries such as life sciences, materials, food, and environmental sciences. The company operates in 35 countries, with a workforce of approximately 7,700 employees and 15 manufacturing facilities worldwide.
Waters has unveiled its new Xevo MRT Mass Spectrometer at the 72nd ASMS Conference. This next-generation instrument employs advanced multi-reflecting time-of-flight technology, offering up to 6x higher resolution and 2x mass accuracy compared to competitors. The Xevo MRT enables faster processing of large sample cohorts, essential for biomedical and epidemiology research. It delivers high resolution, speed, and sensitivity, ensuring reliable data for complex disease studies. The system is compatible with Waters' software, columns, and third-party applications, facilitating comprehensive workflows for metabolomic and lipidomic research. The Xevo MRT will be available for shipment in the second half of 2024.
Waters (NYSE: WAT) has become the first liquid chromatography column provider to receive ACT™ Ecolabel Certification from My Green Lab for 42 of its columns. This certification independently validates the environmental impact of the manufacturing, use, packaging, and disposal of Waters' products. Waters supplies its columns to a wide range of laboratories globally, across various scientific fields. The ACT Ecolabel helps scientists and procurement professionals make sustainable choices without compromising on performance. Waters has a long-standing reputation for quality in LC column chemistries, with innovations like MaxPeak™ Premier High-Performance Surfaces and CORTECS™ Solid Core Particles enhancing lab efficiency. They continue to improve sustainability by using recycled packaging materials and reducing packaging size. This certification underscores Waters' commitment to sustainability and provides a competitive edge in the market.
Waters (NYSE: WAT) will present at the Jefferies 2024 Healthcare Conference. President and CEO Udit Batra Ph.D. will participate in a fireside chat on June 5th, 2024. Waters , a global leader in analytical instruments and software, operates in 35 countries with products available in over 100 countries.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
What industries does Waters Corporation serve?
What are some of Waters Corporation's recent product launches?
How does Waters Corporation contribute to scientific advancements?
What is the significance of the TA Instruments Discovery Hybrid Rheometers?
How is Waters Corporation performing financially?
Where is Waters Corporation headquartered?
How many employees does Waters Corporation have?
What are TA Instruments' main products?
What is the significance of the Oasis WAX/GCB Cartridges?
How can I access Waters Corporation's financial results?
